Johan Lund is a physician and former professor with a PhD from Karolinska Institutet and more than 25 years of experience in drug development across both academia and industry. He has held senior research leadership roles at AstraZeneca, Pfizer, and Celgene, with a focus on inflammation, immunology, and CNS.
At Pfizer, Johan served as Chief Scientific Officer for Inflammation & Immunology and led the development of next-generation JAK inhibitors, resulting in two globally approved marketed drugs as well as an additional late-stage clinical candidate. He is a co-founder of the pharmaceutical companies Kynexis, NeuVentis, and Mesenkia, and has extensive board experience within life science companies, including Olink. Today, he serves as Chairman of the Board at Mesenkia, Neogap Therapeutics, and PharmNovo, and is also operationally active as Chief Scientific Officer at Aqilion.
As Venture Partner at Sciety, Johan brings deep scientific and industrial expertise, contributing to the evaluation of investment opportunities and supporting portfolio companies in translating scientific innovation from research to market.